

# Takashi Kawahara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5769483/publications.pdf>

Version: 2024-02-01

196  
papers

2,475  
citations

218677

26  
h-index

315739

38  
g-index

205  
all docs

205  
docs citations

205  
times ranked

2792  
citing authors

#	ARTICLE	IF	CITATIONS
1	The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer. <i>Asian Journal of Urology</i> , 2021, 8, 332-334.	1.2	2
2	Impact of depression on overactive bladder. <i>International Journal of Urology</i> , 2021, 28, 245-246.	1.0	6
3	A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-naïve prostate cancer. <i>BJUI Compass</i> , 2021, 2, 105-114.	1.3	3
4	Use of metallic and polymeric ureteral stents in malignant ureteral obstruction. <i>BJUI Compass</i> , 2021, 2, 58-63.	1.3	4
5	Complete ureteral stenosis after ureteroscopic lithotripsy successfully managed using a simultaneous retrograde and antegrade flexible ureteroscopic approach. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 246-250.	0.5	2
6	Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium-223. <i>BJUI Compass</i> , 2021, 2, 24-30.	1.3	5
7	Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients. <i>BJUI Compass</i> , 2021, 2, 31-38.	1.3	4
8	A lower psoas muscle index predicts a poorer prognosis in metastatic hormone-naïve prostate cancer. <i>BJUI Compass</i> , 2021, 2, 39-45.	1.3	4
9	A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 3323-3328.	2.2	7
10	Effectiveness and Feasibility of Up-Front Docetaxel Chemotherapy for Japanese Metastatic Hormone-Naïve Prostate Cancer. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1715-1716.	0.6	0
11	Bilateral Encrusted Metallic Stent Successfully Removed by Ureteroscopic Lithotripsy Using a Ho:YAG Laser in a Patient with Malignant Myeloma. <i>Case Reports in Oncology</i> , 2021, 13, 1501-1505.	0.7	0
12	A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control. <i>Case Reports in Oncology</i> , 2020, 12, 688-692.	0.7	2
13	Successful removal of an encrusted metallic ureteral stent using a disposable ureteroscope and Ho:YAG laser lithotripsy. <i>Urolithiasis</i> , 2020, 48, 281-282.	2.0	2
14	Editorial Comment to Ureteric stents: Overview of current clinical applications and economic implications. <i>International Journal of Urology</i> , 2020, 27, 16-16.	1.0	2
15	Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis. <i>World Journal of Urology</i> , 2020, 38, 2477-2484.	2.2	16
16	A lower psoas muscle volume was associated with a higher rate of recurrence in male clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2020, 15, e0226581.	2.5	16
17	Re: Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE. <i>International Journal of Urology</i> , 2020, 27, 188-188.	1.0	3
18	IgG4-Producing MALT Lymphoma in the Renal Hilum. <i>Case Reports in Oncology</i> , 2020, 12, 880-884.	0.7	1

#	ARTICLE	IF	CITATIONS
19	Retroperitoneal Castleman's Disease. <i>Case Reports in Oncology</i> , 2020, 12, 885-889.	0.7	8
20	A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. <i>BMC Cancer</i> , 2020, 20, 919.	2.6	12
21	Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study. <i>BioMed Research International</i> , 2020, 2020, 1-7.	1.9	14
22	Skin Metastasis of Renal Cell Carcinoma. <i>Case Reports in Oncology</i> , 2020, 13, 798-801.	0.7	3
23	Renal Squamous Cell Carcinoma with Staghorn Calculus. <i>Case Reports in Oncology</i> , 2020, 13, 403-407.	0.7	3
24	A Case of Retroperitoneal Ganglioneuroma Accidentally Discovered by Laparoscopic Right Adrenalectomy. <i>Case Reports in Oncology</i> , 2020, 13, 764-767.	0.7	1
25	Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1930-1942.	4.1	17
26	Re: Geriatric screening of frailty in patients with prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 1161-1162.	1.0	5
27	Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer. <i>BMC Urology</i> , 2020, 20, 143.	1.4	1
28	Impact of smoking habit on overactive bladder symptoms and incontinence in women. <i>International Journal of Urology</i> , 2020, 27, 1078-1086.	1.0	15
29	Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 837-838.	1.0	0
30	Impact of Vasectomy on the Development and Progression of Prostate Cancer: Preclinical Evidence. <i>Cancers</i> , 2020, 12, 2295.	3.7	4
31	The impact of smoking on male lower urinary tract symptoms (LUTS). <i>Scientific Reports</i> , 2020, 10, 20212.	3.3	10
32	Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening. <i>Prostate</i> , 2020, 80, 824-830.	2.3	11
33	Pediatric bilateral ureteral stone successfully removed using single-use flexible ureteroscopy with a holmium: YAG laser. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1073-1075.	0.5	0
34	Editorial Comment to Management and treatment options when facing malignant ureteral obstruction. <i>International Journal of Urology</i> , 2020, 27, 598-598.	1.0	0
35	Re: Current treatment strategies for advanced prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 571-571.	1.0	0
36	FOXO1 as a tumor suppressor inactivated via AR/ER <sup>2</sup> signals in urothelial cells. <i>Endocrine-Related Cancer</i> , 2020, 27, 231-244.	3.1	23

#	ARTICLE	IF	CITATIONS
37	A retrospective study on the possible systematic inflammatory response markers to predict the prognosis of patients with bladder cancer undergoing radical cystectomy. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	1.0	5
38	A low psoas muscle volume is associated with a poor prognosis in penile cancer. <i>Oncotarget</i> , 2020, 11, 3526-3530.	1.8	1
39	Title is missing!. , 2020, 15, e0226581.		0
40	Title is missing!. , 2020, 15, e0226581.		0
41	Title is missing!. , 2020, 15, e0226581.		0
42	Title is missing!. , 2020, 15, e0226581.		0
43	A case of allograft ureteral stone successfully treated with antegrade ureteroscopic lithotripsy: use of a 3D-printed model to determine the ideal approach. <i>Urolithiasis</i> , 2019, 47, 467-471.	2.0	5
44	The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday. <i>Case Reports in Oncology</i> , 2019, 12, 568-572.	0.7	4
45	Functional paraganglioma of the bladder: Both radiographicâ€œnegative and laboratoryâ€œnegative case. <i>IJU Case Reports</i> , 2019, 2, 174-177.	0.3	5
46	Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib. <i>Case Reports in Oncology</i> , 2019, 12, 543-547.	0.7	0
47	Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 1161-1162.	1.0	4
48	Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy. <i>Case Reports in Oncology</i> , 2019, 12, 548-553.	0.7	1
49	Inserting a Metallic Ureteral Stent Using an Antegrade Approach Freed a Patient from Nephrostomy Created due to Hydronephrosis Caused by Bladder Cancer. <i>Case Reports in Oncology</i> , 2019, 12, 560-563.	0.7	3
50	Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer. <i>Urologia Internationalis</i> , 2019, 103, 279-284.	1.3	11
51	Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer. <i>Case Reports in Oncology</i> , 2019, 12, 603-607.	0.7	5
52	Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis. <i>Case Reports in Oncology</i> , 2019, 12, 608-612.	0.7	8
53	Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia. <i>Case Reports in Oncology</i> , 2019, 12, 589-594.	0.7	3
54	Successful treatment of ureteral stricture after total hysterectomy: An antegrade ureteroscopic approach facilitates the insertion of a guidewire for endoscopic dilation. <i>IJU Case Reports</i> , 2019, 2, 140-142.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate-specific antigen level and improvement in radiographic findings. IJU Case Reports, 2019, 2, 143-145.	0.3	3
56	Expression of PD-L1 and CTLA-4 in female urethral carcinoma. IJU Case Reports, 2019, 2, 23-26.	0.3	1
57	Successful treatment with sorafenib for sunitinib-refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib. IJU Case Reports, 2019, 2, 43-46.	0.3	1
58	High orchiectomy and ipsilateral testicular sperm extraction in a man with a testicular tumor and Klinefelter syndrome: A case report. IJU Case Reports, 2019, 2, 65-68.	0.3	2
59	Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. BMC Cancer, 2019, 19, 331.	2.6	19
60	Clear cell adenocarcinoma of the prostatic urethra: A case report. IJU Case Reports, 2019, 2, 19-22.	0.3	3
61	Spontaneous adrenal hemorrhage with dehydroepiandrosterone-sulfate elevation in a patient with suspected adrenal cortical carcinoma. IJU Case Reports, 2019, 2, 102-104.	0.3	0
62	Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide. BioMed Research International, 2019, 2019, 1-5.	1.9	25
63	The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer. BioMed Research International, 2019, 2019, 1-5.	1.9	4
64	Distribution of androgen receptor expression in the urinary bladder. International Journal of Urology, 2019, 26, 305-306.	1.0	10
65	Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Negative Prostate Cancer. Urologia Internationalis, 2019, 102, 37-42.	1.3	1
66	Management of urethral stricture: High-pressure balloon dilation versus optical internal urethrotomy. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O34-O37.	1.3	3
67	Response to Letter to the Editor Regarding "Neutrophil-to-Lymphocyte Ratio in Renal Transplant Patients". Experimental and Clinical Transplantation, 2019, 17, 129-129.	0.5	0
68	FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 739-744.	2.3	15
69	Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report. Clinical Case Reports (discontinued), 2018, 6, 391-394.	0.5	3
70	Extramedullary plasmacytoma of the testis: A case report. Urology Case Reports, 2018, 16, 101-103.	0.3	5
71	Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report. Journal of Medical Case Reports, 2018, 12, 32.	0.8	11
72	The Use of a Metal Stent in the Treatment of Ureteral Stricture in a Patient Who Had Undergone Radical Cystectomy with the Creation of an Ileal Conduit. Case Reports in Oncology, 2018, 11, 159-163.	0.7	2

#	ARTICLE	IF	CITATIONS
73	Female urethral diverticular carcinoma treated by multimodality therapies: A case report. <i>Urology Case Reports</i> , 2018, 17, 131-133.	0.3	0
74	Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate. <i>Molecular and Clinical Oncology</i> , 2018, 8, 587-591.	1.0	12
75	Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naïve Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 142-148.	1.9	29
76	Prostaglandin receptors induce urothelial tumorigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. <i>British Journal of Cancer</i> , 2018, 118, 213-223.	6.4	35
77	Prostate Basal Cell Carcinoma: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 138-142.	0.7	1
78	Editorial Comment to Superiority of dutasteride 0.5Âmg and tamsulosin 0.2Âmg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men. <i>International Journal of Urology</i> , 2018, 25, 951-952.	1.0	0
79	A Longer History of Hemodialysis Can Lead to Sarcopenia in Renal Transplantation Patients. <i>Transplantation Proceedings</i> , 2018, 50, 2447-2450.	0.6	11
80	Sarcomatoid Variant of Bladder Carcinoma: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 633-637.	0.7	1
81	The analysis of human papillomavirus DNA in penile cancer tissue by in-situ hybridization. <i>Oncology Letters</i> , 2018, 15, 8102-8106.	1.8	7
82	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. <i>Human Molecular Genetics</i> , 2018, 27, 2712-2724.	2.9	14
83	Primary amelanotic malignant melanoma of the male urethra with inguinal lymph node metastasis successfully controlled by nivolumab: A case report. <i>Urology Case Reports</i> , 2018, 18, 54-56.	0.3	11
84	Adrenal Hemangioma: A Case of Retroperitoneal Tumor. <i>Case Reports in Medicine</i> , 2018, 2018, 1-4.	0.7	1
85	Comparison of Outcomes between Two Methods to Extract Stone Fragments during Flexible Ureteroscopic Lithotripsy. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	6
86	The half-loop transurethral incision technique for bilateral ureterocele in adult. <i>Urology Case Reports</i> , 2018, 18, 6-8.	0.3	0
87	Expression of receptor activator of nuclear factor kappa ligand in bladder cancer. <i>International Journal of Urology</i> , 2018, 25, 901-902.	1.0	16
88	Renal Cell Carcinoma in a Horseshoe Kidney Treated with Laparoscopic Partial Nephrectomy. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-3.	0.3	11
89	Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract. <i>International Journal of Molecular Sciences</i> , 2018, 19, 777.	4.1	9
90	An infertile patient with Y chromosome b1/b3 deletion presenting with congenital bilateral absence of the vas deferens with normal spermatogenesis. <i>Clinical and Experimental Reproductive Medicine</i> , 2018, 45, 48-51.	1.5	2

#	ARTICLE	IF	CITATIONS
91	Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. <i>BMC Cancer</i> , 2018, 18, 501.	2.6	12
92	Fluorescent Light-Guided Cystoscopy with 5-ALA Aids in Accurate Surgical Margin Detection for TURBO: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 164-167.	0.7	1
93	Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure. <i>BMC Urology</i> , 2018, 18, 35.	1.4	15
94	Successful onco-testicular sperm extraction from a testicular cancer patient with a single testis and azoospermia. <i>Clinical and Experimental Reproductive Medicine</i> , 2018, 45, 44-47.	1.5	9
95	Value of bone scan index for predicting overall survival among patients treated with radium-223 for bone metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 216-216.	1.6	3
96	A new prediction model for operative time of flexible ureteroscopy with lithotripsy for the treatment of renal stones. <i>PLoS ONE</i> , 2018, 13, e0192597.	2.5	22
97	Evaluation of ability of low-molecular-weight protein tyrosine phosphatase expression to predict primary hormone therapy efficacy among men with metastatic hormone-naïve prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 316-316.	1.6	0
98	Evaluation of ability of OR51T1 expression to predict primary hormone therapy efficacy among men with hormone-naïve metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 317-317.	1.6	0
99	ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor. <i>American Journal of Cancer Research</i> , 2018, 8, 2325-2336.	1.4	11
100	Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 472-478.	1.9	13
101	RANK/RANKL expression in prostate cancer. <i>International Journal of Surgery Case Reports</i> , 2017, 30, 106-107.	0.6	6
102	Foreign body in the bladder: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 32, 22-24.	0.6	10
103	Editorial Comment from Dr Kawahara to Prevention and treatment of symptoms associated with indwelling ureteral stents: A systematic review. <i>International Journal of Urology</i> , 2017, 24, 260-260.	1.0	6
104	Measurement of serum isoform [â€“2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2â€“10â€“ng/ml. <i>Scandinavian Journal of Urology</i> , 2017, 51, 251-257.	1.0	11
105	NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract. <i>Translational Oncology</i> , 2017, 10, 318-323.	3.7	12
106	Effect of density gradient centrifugation on reactive oxygen species in human semen. <i>Systems Biology in Reproductive Medicine</i> , 2017, 63, 192-198.	2.1	26
107	Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer. <i>Urologia Internationalis</i> , 2017, 99, 400-405.	1.3	5
108	Lack of an association between the aPKCÎ»/Î±1 expression in prostate cancer and the patient outcomes. <i>International Journal of Surgery Case Reports</i> , 2017, 37, 180-182.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naïve Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1073-e1080.	1.9	19
110	Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 607.e9-607.e14.	1.6	5
111	Onco-testicular sperm extraction (onco-TESE) for bilateral testicular tumors: two case reports. <i>Journal of Medical Case Reports</i> , 2017, 11, 139.	0.8	16
112	The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis. <i>BMC Urology</i> , 2017, 17, 49.	1.4	14
113	Port site recurrence after laparoscopic radical nephrectomy: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 151.	0.8	5
114	Inflammatory Myofibroblastic Tumor in the Bladder: A Case Report. <i>Case Reports in Oncology</i> , 2017, 9, 554-558.	0.7	3
115	Ductal Adenocarcinoma of the Prostate: A Case Report. <i>Case Reports in Oncology</i> , 2017, 9, 802-805.	0.7	3
116	The Effects of Different Doses and Patterns of Docetaxel Chemotherapy in Japanese Patients with Castration-Resistant Prostate Cancer. <i>Current Urology</i> , 2017, 10, 166-168.	0.6	1
117	Xanthogranulomatous Pyelonephritis with Incomplete Double Ureter. <i>Case Reports in Medicine</i> , 2017, 2017, 1-3.	0.7	2
118	A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. <i>BioMed Research International</i> , 2017, 2017, 1-4.	1.9	25
119	Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy. <i>BioMed Research International</i> , 2017, 2017, 1-5.	1.9	27
120	Effect of Amplatz Sheath on Cystolithotripsy for Women with Large Bladder Stone. <i>BioMed Research International</i> , 2017, 2017, 1-4.	1.9	1
121	A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. <i>BMC Urology</i> , 2017, 17, 87.	1.4	40
122	Enterogenous cyst of pediatric testis: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 207.	0.8	3
123	Ureter metastatic castration-resistant prostate cancer: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 215.	0.8	2
124	Large cell neuroendocrine carcinoma of the kidney with cardiac metastasis: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 297.	0.8	7
125	Paraganglioma in the bladder: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 306.	0.8	19
126	A low psoas muscle volume predicts longer hospitalization and cancer recurrence in upper urinary tract urothelial carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 8, 320-322.	1.0	10



#	ARTICLE	IF	CITATIONS
127	ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. <i>Oncotarget</i> , 2016, 7, 53599-53610.	1.8	26
128	Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. <i>Oncotarget</i> , 2016, 7, 49169-49179.	1.8	56
129	Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade. <i>BioMed Research International</i> , 2016, 2016, 1-7.	1.9	14
130	Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy. <i>BioMed Research International</i> , 2016, 2016, 1-6.	1.9	15
131	Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. <i>BioMed Research International</i> , 2016, 2016, 1-5.	1.9	11
132	Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine. <i>Prostate</i> , 2016, 76, 744-756.	2.3	19
133	Risk factors of systemic inflammation response syndrome after endoscopic combined intrarenal surgery in the modified Valdivia position. <i>International Journal of Urology</i> , 2016, 23, 687-692.	1.0	13
134	Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score. <i>BMC Urology</i> , 2016, 16, 32.	1.4	7
135	Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1042-1046.	1.3	13
136	Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. <i>BMC Cancer</i> , 2016, 16, 109.	2.6	29
137	Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. <i>BMC Cancer</i> , 2016, 16, 111.	2.6	35
138	Increased neutrophil-to-lymphocyte ratio is associated with disease-specific mortality in patients with penile cancer. <i>BMC Cancer</i> , 2016, 16, 396.	2.6	20
139	Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 432.e15-432.e23.	1.6	33
140	Epidermal Cyst in the Scrotum Successfully Treated while Preserving the Testis: A Case Report. <i>Case Reports in Oncology</i> , 2016, 9, 235-240.	0.7	3
141	Developing a preoperative predictive model for ureteral length for ureteral stent insertion. <i>BMC Urology</i> , 2016, 16, 70.	1.4	10
142	Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. <i>Molecular Carcinogenesis</i> , 2016, 55, 161-169.	2.7	27
143	Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naïve prostate cancer patients with bone metastases. <i>BMC Cancer</i> , 2016, 16, 128.	2.6	24
144	Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 48.	0.8	6

#	ARTICLE	IF	CITATIONS
145	The Neutrophil-to-Lymphocyte Ratio before Repeat Prostate Needle Biopsy for Predicting Prostate Cancer. <i>Urologia Internationalis</i> , 2016, 96, 123-124.	1.3	7
146	Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. <i>BMC Cancer</i> , 2016, 16, 185.	2.6	46
147	Predicting the mineral composition of ureteral stone using non-contrast computed tomography. <i>Urolithiasis</i> , 2016, 44, 231-239.	2.0	17
148	The role of NFATc1 in prostate cancer progression: Cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion. <i>Prostate</i> , 2015, 75, 573-584.	2.3	39
149	Retroperitoneal Schwannoma in the Renal Hilum: A Case Report. <i>Case Reports in Oncology</i> , 2015, 8, 394-398.	0.7	2
150	Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. <i>Oncotarget</i> , 2015, 6, 1582-1593.	1.8	52
151	Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression. <i>Molecular Endocrinology</i> , 2015, 29, 1486-1497.	3.7	34
152	Ureteroscopy-assisted retrograde nephrostomy (UARN) without ureteral access sheath (UAS). <i>International Journal of Surgery Case Reports</i> , 2015, 10, 56-58.	0.6	0
153	Development and internal validation of a nomogram for predicting stone-free status after flexible ureteroscopy for renal stones. <i>BJU International</i> , 2015, 115, 446-451.	2.5	60
154	Double ureteral access sheath (UAS) technique for complicated distal ureteral stone. <i>Urolithiasis</i> , 2015, 43, 99-100.	2.0	0
155	Ureteroscopy-assisted retrograde nephrostomy for a large and obstructive renal pelvic stone: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 44.	0.8	1
156	Ureteroscopy-Assisted Biopsy for a Retroperitoneal Tumor: A Case Report. <i>Case Reports in Oncology</i> , 2015, 8, 279-284.	0.7	0
157	Development and Internal Validation of a Classification System for Predicting Success Rates After Endoscopic Combined Intrarenal Surgery in the Modified Valdivia Position for Large Renal Stones. <i>Urology</i> , 2015, 86, 697-702.	1.0	24
158	Clinical factors prolonging the operative time of flexible ureteroscopy for renal stones: a single-center analysis. <i>Urolithiasis</i> , 2015, 43, 467-475.	2.0	20
159	Discolored Ureteral Stents: Findings in Urinalysis and Urine Culture. <i>PLoS ONE</i> , 2015, 10, e0122984.	2.5	7
160	ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. <i>Oncotarget</i> , 2015, 6, 29860-29876.	1.8	83
161	Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. <i>Oncotarget</i> , 2015, 6, 32169-32176.	1.8	53
162	Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation. <i>American Journal of Cancer Research</i> , 2015, 5, 2959-68.	1.4	20

#	ARTICLE	IF	CITATIONS
163	Nonsteroidal Anti-Inflammatory Drugs and Prostatic Diseases. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	29
164	Reduced Glucocorticoid Receptor Expression Predicts Bladder Tumor Recurrence and Progression. <i>American Journal of Clinical Pathology</i> , 2014, 142, 157-164.	0.7	31
165	Loss of GATA3 in bladder cancer promotes cell migration and invasion. <i>Cancer Biology and Therapy</i> , 2014, 15, 428-435.	3.4	46
166	Correlation between the operation time using two different power settings of a Ho: YAG laser: laser power doesn't influence lithotripsy time. <i>BMC Research Notes</i> , 2013, 6, 80.	1.4	5
167	Early ureteral catheter removal after ureteroscopic lithotripsy using ureteral access sheath. <i>Urolithiasis</i> , 2013, 41, 31-35.	2.0	9
168	Authors' Response to Chew and Lange. <i>Journal of Endourology</i> , 2013, 27, 507-507.	2.1	1
169	Ureteroscopy-Assisted Retrograde Nephrostomy (UARN) after Anatomic Nephrolithotomy. <i>Case Reports in Medicine</i> , 2012, 2012, 1-4.	0.7	1
170	Encrusted Ureteral Stent Retrieval Using Flexible Ureteroscopy with a Ho: YAG Laser. <i>Case Reports in Medicine</i> , 2012, 2012, 1-4.	0.7	8
171	Predictive Value of Attenuation Coefficients Measured as Hounsfield Units on Noncontrast Computed Tomography During Flexible Ureteroscopy with Holmium Laser Lithotripsy: A Single-Center Experience. <i>Journal of Endourology</i> , 2012, 26, 1125-1130.	2.1	63
172	Authors' Response to Letter to the Editor. <i>Journal of Endourology</i> , 2012, 26, 926-926.	2.1	0
173	Choosing an Appropriate Length of Loop Type Ureteral Stent Using Direct Ureteral Length Measurement. <i>Urologia Internationalis</i> , 2012, 88, 48-53.	1.3	24
174	Ureteral Stent Exchange under Fluoroscopic Guidance Using the Crochet Hook Technique in Women. <i>Urologia Internationalis</i> , 2012, 88, 322-325.	1.3	12
175	Ureteroscopy-Assisted Retrograde Nephrostomy for Percutaneous Nephrolithotomy after Urinary Diversion. <i>Case Reports in Nephrology and Urology</i> , 2012, 2, 113-117.	1.5	4
176	Ureteroscopy Assisted Retrograde Nephrostomy for Complete Staghorn Renal Calculi. <i>Current Urology</i> , 2012, 6, 102-105.	0.6	2
177	Ureteroscopy-assisted retrograde nephrostomy (UARN) for an incomplete double ureter. <i>Urological Research</i> , 2012, 40, 781-782.	1.5	7
178	Changing to a loop-type ureteral stent decreases patients' stent-related symptoms. <i>Urological Research</i> , 2012, 40, 763-767.	1.5	26
179	Amplatz Sheath for Cystolithotripsy Using Ho: YAG Laser in Female Patients. <i>Urology</i> , 2012, 80, 1154-1155.	1.0	7
180	Stone area and volume are correlated with operative time for cystolithotripsy for bladder calculi using a holmium: yttrium garnet laser. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 298-303.	1.4	13

#	ARTICLE	IF	CITATIONS
181	The Most Reliable Preoperative Assessment of Renal Stone Burden as a Predictor of Stone-free Status After Flexible Ureteroscopy With Holmium Laser Lithotripsy: A Single-center Experience. <i>Urology</i> , 2012, 80, 524-528.	1.0	78
182	Which is the best method to estimate the actual ureteral length in patients undergoing ureteral stent placement?. <i>International Journal of Urology</i> , 2012, 19, 634-638.	1.0	15
183	Ureteral Stent Encrustation, Incrustation, and Coloring: Morbidity Related to Indwelling Times. <i>Journal of Endourology</i> , 2012, 26, 178-182.	2.1	158
184	Ureteroscopy-assisted retrograde nephrostomy for lower calyx calculi in horseshoe kidney: two case reports. <i>Journal of Medical Case Reports</i> , 2012, 6, 194.	0.8	3
185	Ureteral Stent Retrieval Using the Crochet Hook Technique in Females. <i>PLoS ONE</i> , 2012, 7, e29292.	2.5	23
186	Effectiveness of Ureteroscopy-Assisted Retrograde Nephrostomy (UARN) for Percutaneous Nephrolithotomy (PCNL). <i>PLoS ONE</i> , 2012, 7, e52149.	2.5	12
187	Ureteroscopic removal of forgotten ureteral stent. <i>BMJ Case Reports</i> , 2012, 2012, bcr0220125736-bcr0220125736.	0.5	7
188	Preoperative stenting for ureteroscopic lithotripsy for a large renal stone. <i>International Journal of Urology</i> , 2012, 19, 881-885.	1.0	49
189	Ureteroscopy assisted retrograde nephrostomy: a new technique for percutaneous nephrolithotomy (PCNL). <i>BJU International</i> , 2012, 110, 588-590.	2.5	47
190	Ureteroscopy-Assisted Retrograde Nephrostomy. <i>Videourology (New Rochelle, N Y)</i> , 2012, 26, .	0.1	5
191	Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel. <i>PLoS ONE</i> , 2012, 7, e48186.	2.5	27
192	Ureteroscopy-assisted retrograde nephrostomy for an obese patient. <i>Indian Journal of Urology</i> , 2012, 28, 439.	0.6	2
193	High-grade invasive urothelial carcinoma with focal plasmacytoid differentiation successfully treated by transurethral resection followed by chemoradiotherapy. <i>International Journal of Urology</i> , 2011, 18, 851-853.	1.0	8
194	Analysis of NSAID-Activated Gene 1 Expression in Prostate Cancer. <i>Urologia Internationalis</i> , 2010, 84, 198-202.	1.3	17
195	A case of infective endocarditis after transurethral prostatic resection. <i>Urology Annals</i> , 2010, 2, 83.	0.6	2
196	Microsurgical varicocelectomy for intratesticular varicocele with a history of orchiopexy for undescended testis. <i>IJU Case Reports</i> , 0, .	0.3	0